Paper30065564
Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis.
Jiang XW and 3 others. World J Gastroenterol, 2018. Cited by 25 papers, by iCite.
Cite this record
ConductScience Library. Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis. Papers, record 30065564. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30065564
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antiviral Agents | Major topic |
| Coinfection | Major topic |
| Hepatitis B | Major topic |
| Hepatitis B virus | Major topic |
| Hepatitis C | Major topic |
| Antibiotic Prophylaxis | |
| Disease Progression | |
| Guanine | |
| Hepatitis B Surface Antigens | |
| Humans | |
| Incidence | |
| Interferons | |
| Recurrence | |
| Tenofovir | |
| Treatment Outcome | |
| Virus Activation |
Source PubMed
References49
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19669238 | Dual chronic hepatitis B virus and hepatitis C virus infection. | Hepatol Int | 2009 | https://conductscience.org/library/papers/19669238 | PubMed |
| 2 | 28230928 | Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals. | J Gastroenterol Hepatol | 2017 | https://conductscience.org/library/papers/28230928 | PubMed |
| 3 | 19596477 | Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. | J Hepatol | 2009 | https://conductscience.org/library/papers/19596477 | PubMed |
| 4 | 27667367 | EASL Recommendations on Treatment of Hepatitis C 2016. | J Hepatol | 2017 | https://conductscience.org/library/papers/27667367 | PubMed |
| 5 | 28552801 | Interferon-Free Regimens in Hepatitis B Surface Antigen/Anti-Hepatitis C Virus Positive Patients: The Need to Control Hepatitis B Virus Replication to Avoid Hepatitis B Virus Reactivation. | Clin Gastroenterol Hepatol | 2017 | https://conductscience.org/library/papers/28552801 | PubMed |
| 6 | 17302256 | Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy. | Antivir Ther | 2006 | https://conductscience.org/library/papers/17302256 | PubMed |
| 7 | 11693335 | High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. | Am J Gastroenterol | 2001 | https://conductscience.org/library/papers/11693335 | PubMed |
| 8 | 27394647 | The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. | Lancet | 2016 | https://conductscience.org/library/papers/27394647 | PubMed |
| 9 | 28195337 | Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis. | Hepatology | 2017 | https://conductscience.org/library/papers/28195337 | PubMed |
| 10 | 19812441 | The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin. | Antivir Ther | 2009 | https://conductscience.org/library/papers/19812441 | PubMed |
| 11 | 19084016 | Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. | Gastroenterology | 2009 | https://conductscience.org/library/papers/19084016 | PubMed |
| 12 | 22102386 | Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus. | Korean J Hepatol | 2011 | https://conductscience.org/library/papers/22102386 | PubMed |
| 13 | 27367295 | Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV. | Antivir Ther | 2016 | https://conductscience.org/library/papers/27367295 | PubMed |
| 14 | 28206681 | Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen. | Aliment Pharmacol Ther | 2017 | https://conductscience.org/library/papers/28206681 | PubMed |
| 15 | 18490796 | Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers. | Neth J Med | 2008 | https://conductscience.org/library/papers/18490796 | PubMed |
| 16 | 18490077 | The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. | J Hepatol | 2008 | https://conductscience.org/library/papers/18490077 | PubMed |
| 17 | 31816111 | Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. | Hepatology | 2020 | https://conductscience.org/library/papers/31816111 | PubMed |
| 18 | 17376043 | Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patients. | J Gastroenterol Hepatol | 2007 | https://conductscience.org/library/papers/17376043 | PubMed |
| 19 | 28437794 | Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System. | Ann Intern Med | 2017 | https://conductscience.org/library/papers/28437794 | PubMed |
| 20 | 9282824 | Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. | J Interferon Cytokine Res | 1997 | https://conductscience.org/library/papers/9282824 | PubMed |
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40445953 | Risk of HBV reactivation in HBV/HCV-co-infected HCV-treated patients: A single-center study. | PLoS One | 2025 | https://conductscience.org/library/papers/40445953 | PubMed |
| 38881210 | Hepatitis B transmission/reactivation associated with Hepatitis B core antibody and Hepatitis C nucleic acid testing positive organs: A report from the Organ Procurement and Transplantation Network Disease Transmission Advisory Committee. | Transpl Infect Dis | 2024 | https://conductscience.org/library/papers/38881210 | PubMed |
| 37056462 | Synthesis and biological evaluation of esculetin derivatives as potential anti-HBV agents. | Med Chem Res | 2023 | https://conductscience.org/library/papers/37056462 | PubMed |
| 37022602 | Low Rate of Hepatitis B Reactivation Among Patients with Chronic Hepatitis C During Direct Acting Antiviral Therapy. | Dig Dis Sci | 2023 | https://conductscience.org/library/papers/37022602 | PubMed |
| 36815093 | Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance. | J Hepatocell Carcinoma | 2023 | https://conductscience.org/library/papers/36815093 | PubMed |
| 36556178 | Direct-Acting Antivirals and the Risk of Hepatitis B Reactivation in Hepatitis B and C Co-Infected Patients: A Systematic Review and Meta-Analysis. | J Pers Med | 2022 | https://conductscience.org/library/papers/36556178 | PubMed |
| 36158908 | Challenge of managing hepatitis B virus and hepatitis C virus infections in resource-limited settings. | World J Hepatol | 2022 | https://conductscience.org/library/papers/36158908 | PubMed |
| 35663152 | The dilemma of cytomegalovirus and hepatitis B virus interaction. | Gastroenterol Rep (Oxf) | 2022 | https://conductscience.org/library/papers/35663152 | PubMed |
| 34378349 | Profiling the physiological pitfalls of anti-hepatitis C direct-acting agents in budding yeast. | Microb Biotechnol | 2021 | https://conductscience.org/library/papers/34378349 | PubMed |
| 32108916 | Direct-acting antiviral treatment downregulates immune checkpoint inhibitor expression in patients with chronic hepatitis C. | Clin Exp Med | 2020 | https://conductscience.org/library/papers/32108916 | PubMed |
| 32102898 | Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. | Clin Microbiol Rev | 2020 | https://conductscience.org/library/papers/32102898 | PubMed |
| 31969598 | Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway. | Sci Rep | 2020 | https://conductscience.org/library/papers/31969598 | PubMed |
| 31413526 | Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions. | World J Gastroenterol | 2019 | https://conductscience.org/library/papers/31413526 | PubMed |
| 30687740 | Recent Advances in HBV Reactivation Research. | Biomed Res Int | 2018 | https://conductscience.org/library/papers/30687740 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30065564
GET https://conductscience.org/api/papers/v1/30065564/references?page=2